MG-7 peptide-MHC complex (MG7-pMHC)

The MG-7 peptide-MHC complex is a specialized immunological target formed when the MG-7 gastric cancer-associated antigen (MG7-Ag) is processed and presented by dendritic cells or malignant cells. MG7-Ag is a highly specific biomarker for gastric carcinoma, showing minimal expression in normal tissues but high prevalence in malignant and precancerous gastric lesions such as intestinal metaplasia (Fan et al., 2005, PubMed). The therapeutic strategy typically involves pulsing dendritic cells with MG7 peptides, which then present these antigens via Major Histocompatibility Complex (MHC) molecules to engage and activate cognate T-cell receptors (TCRs) on naive T cells. This engagement triggers the expansion of MG7-specific cytotoxic T lymphocytes (CTLs) capable of recognizing and lysing tumor cells that express the MG7 antigen (Guo et al., 2005, World J Gastroenterol). This target is central to the development of personalized cancer vaccines and TCR-based adoptive cell therapies aimed at treating gastric and colorectal cancers. Clinical interest in this complex stems from its high specificity and the potential to overcome the immunosuppressive tumor microenvironment by enhancing antigen-specific T-cell responses (Ren et al., 2012, Oncology Letters).

Other names

MG-7 antigen-presenting dendritic cellMG-7 peptide–MHC complex engaging T-cell receptorMG7-Ag/MHC complexMG7-AgGastric cancer-associated antigen MG7

Activation of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) through the high-affinity interaction between the MG7 peptide-MHC complex on the surface of dendritic cells (or tumor cells) and the cognate T-cell receptor (TCR), leading to the release of perforins and granzymes that induce tumor cell apoptosis.